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ABSTRACT
Survivin (also known as BIRC5) is a cancer-associated protein that
exists in several locations in the cell. Its cytoplasmic residence in
interphase cells is governed by CRM1 (also known as XPO1)-
mediated nuclear exportation, and its localisation duringmitosis to the
centromeres and midzone microtubules is that of a canonical
chromosomal passenger protein. In addition to these well-
established locations, survivin is also a mitochondrial protein, but
how it gets there and its function therein is presently unclear. Here, we
show that the first ten amino acids at the N-terminus of survivin are
sufficient to target GFP to the mitochondria in vivo, and ectopic
expression of this decapeptide decreases cell adhesion and
accelerates proliferation. The data support a signalling mechanism
in which this decapeptide regulates the tyrosine kinase Src, leading to
reduced focal adhesion plaques and disruption of F-actin
organisation. This strongly suggests that the N-terminus of survivin
is a mitochondrial-targeting sequence that regulates Src, and that
survivin acts in concert with Src to promote tumorigenesis.
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INTRODUCTION
Survivin (also known as BIRC5) is a cancer-associated protein that
inhibits cell death and is essential for mitosis (Altieri, 2008).
Although its expression is usually confined to G2-phase and
mitosis, survivin is often expressed throughout the cell cycle in
cancer. Its abundance in tumours correlates with increased
resistance to chemotherapy and radiation, treatments lethal to cells
through DNA damage and apoptosis induction. When present in
interphase, survivin is predominantly cytoplasmic and is actively
shuttled out of the nucleus by CRM1 (also known as exportin,
XPO1) (Colnaghi et al., 2006; Knauer et al., 2007; Rodríguez et al.,
2002; Stauber et al., 2007). Nuclear expression of survivin has been
correlated with relapse-free prognosis for some cancer patients
(Knauer et al., 2007) and longer survival in others (Okada et al.,
2001; Tonini et al., 2005), although several papers argue the
opposite (see Wheatley, 2011). Supporting the cytoprotective role
of cytoplasmic survivin, we and others have shown that mutating its
nuclear export signal, or forcing nuclear location, abrogates
cytoprotection from irradiation and apoptosis (Colnaghi et al.,
2006; Connell et al., 2008; Knauer et al., 2007), and might have
therapeutic potential (Rexhepaj et al., 2010).
In addition to the cytoplasmic and nuclear pools, in cancer cells,
some survivin resides in the mitochondria (Dohi et al., 2004). As for
other mitochondrial and cytoplasmic proteins (Itoh et al., 2005),
when overexpressed the mitochondrial pool of survivin is eclipsed
by the abundant cytoplasmic population. However, subcellular
fractionation has clearly shown its presence in this organelle, and its
abundance increases in response to hypoxia and treatment with
adriamycin or etoposide (Ceballos-Cancino et al., 2007; Dohi et al.,
2004). Despite its early detection in mitochondria, how survivin
enters mitochondria and functions therein remains unclear. Kang
et al. (2011) have shown that a cofactor called aryl hydrocarbon
(AH)-receptor-interacting protein facilitates entry of survivin into
mitochondria by interacting with its C-terminal residue, D142
(Kang et al., 2011). Alternatively survivin might be chaperoned into
mitochondria by Hsp90 family proteins, which interact with its
baculovirus-inhibitor-of-apoptosis repeat domain (Fortugno et al.,
2003).
As mitochondria are instrumental in apoptosis, one might expect
the primary function of mitochondrial survivin to relate to its status
as an inhibitor of apoptosis protein. In fact, Dohi et al. (2004) have
found survivin had to be released from mitochondria to effectively
counter cell death. The functional relevance of mitochondrial
survivin might also be linked to its interaction with Hsp90 family
proteins (Fortugno et al., 2003), as treatment with the survivin–
Hsp90 antagonist shepherdin compromises mitochondrial integrity
(Hoel et al., 2012; Vishal et al., 2011). Survivin might also
influence mitochondrial dynamics by modulating the sculpting
proteins, Drp1 (also known as DNM1L) and Fis1 (Hagenbuchner
et al., 2013). Either way, one would expect that compromising
mitochondrial integrity would affect apoptosis and metabolism
(Hagenbuchner et al., 2013; Rivadeneira et al., 2015).
Src is a non-receptor tyrosine kinase that is targeted to the plasma
membrane by myristoylation and is frequently overexpressed or
aberrantly activated in cancer, particularly epithelial cancers
(Frame, 2002; Giaccone and Zucali, 2008). Src, the first proto-
oncogene identified, was discovered as the endogenous homologue
of the oncogene, v-Src. Src is involved in many cellular events and,
like survivin, interfaces life and death at several levels. At the
plasma membrane, Src regulates cell–matrix attachment through
focal adhesions and the F-actin cytoskeleton. However, somewhat
paradoxically, prolonged Src activity prevents focal adhesion
turnover causing increased adhesion. Src can be directed to
mitochondria by proline-rich cofactors that interact with its SH3
domain including Dok4 (Itoh et al., 2005), and T-cell leukemia
virus type-1 protein (Tibaldi et al., 2011).
This study aimed to determine how survivin enters the
mitochondria and its function therein. We report that expression
of an N-terminal survivin truncation lacking the first ten residues
causes increases in the numbers of focal adhesions and abundanceReceived 16 November 2015; Accepted 20 May 2016
School of Life Sciences, University of Nottingham, Queen’s Medical Centre,
Nottingham NG7 2UH, UK.
*Author for correspondence (sally.wheatley@nottingham.ac.uk)
S.P.W., 0000-0002-9550-8979
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution and reproduction in any medium provided that the original work is properly attributed.
2707
© 2016. Published by The Company of Biologists Ltd | Journal of Cell Science (2016) 129, 2707-2712 doi:10.1242/jcs.183277
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
of F-actin in cells, which we attribute to its ability to activate Src.
Conversely, adhesion is decreased following the expression of the
N-terminal decapeptide alone. Finally, we show that the N-terminus
is a mitochondrial-targeting sequence (MTS) that binds Src.
Collectively, these data suggest that survivin liaises with Src to
promote tumorigenesis.
RESULTS AND DISCUSSION
Cells expressing survivin11–142–GFP are highly adherent
We recently showed that HeLa cells expressing an N-terminal
truncation of survivin comprising amino acids 11–142,
survivin11–142–GFP were resistant to apoptosis and sensitised to
irradiation (Wheatley, 2015). During handling, we also noticed
that they were more adherent than controls, suggesting that focal
adhesions were affected. Therefore, we grew cells on glass
coverslips, fixed and probed them with anti-vinculin antibodies
and counterstained with Rhodamine–phalloidin to visualise
F-actin. Compared with GFP controls, survivin11–142–GFP cells
had more prominent focal adhesions and much stronger F-actin
fibres (Fig. 1A).
The N-terminus of survivin regulates Src activity
It is well established that the formation and dynamics of focal
adhesions and F-actin integrity are dependent on Src activity
Fig. 1. The N-terminus of survivin
regulates Src. (A) HeLa cells
expressing GFP or survivin11–142–GFP
(green) were grown on glass
coverslips, fixed and probed to
visualise focal adhesions with anti-
vinculin antibodies (blue) and F-actin
with Rhodamine–phalloidin (red). Scale
bars: 5 µm. (B) Asynchronous cell
lysates immunoblotted with anti-
phospho-Src, anti-Src and anti-tubulin
antibodies. Anti-GFP verified
expression of each construct.
(C) Src co-immunoprecipitated
(in experiments using GFP Trap beads)
with survivin1–10–GFP and
survivin–GFP, but not GFP
or survivin11–142–GFP. 11-142-GFP,
survivin11–142–GFP; 1-10-GFP,
survivin1–10–GFP;SVN-GFP,
survivin–GFP.
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(Frame, 2002). Thus, we examined whether Src activity was altered
in these cells. Lysates from cells expressing GFP, survivin–GFP or
survivin11-142–GFPwere assessed for changes in Src expression and
activity by immunoblotting with pan-Src antibodies and antibodies
against its tyrosine-phosphorylated form (phospho-SrcY416),
respectively. Strikingly, although Src was present at similar levels
in all samples, its activity was highly elevated in cells expressing
survivin11–142–GFP (Fig. 1B).
As truncating the first ten residues of survivin had such a profound
effect on adhesion and Src activity, we turned our attention to the N-
terminus itself. Interestingly, three of these ten residues (residues 4,
6 and 7) are prolines: MGAPPTLPAW. Although enrichment of
prolines within this decapeptide might explain why structural data
was not forthcoming (Verdecia et al., 2000; Sun et al., 2005), from a
functional perspective it suggests the potential to interact with
SH3-domain-containing proteins such as Src. To test this, we
checked whether these first ten amino acids (survivin1–10–GFP), and
survivin–GFP, could immunoprecipitate endogenous Src, and
gained a positive result in each case (Fig. 1C). Mediation of Src–
survivin interaction by the N-terminus was further corroborated by
the inability of survivin11–142–GFP, to co-immunoprecipitate Src in
this experiment. Thus, we conclude that these N-terminal ten
residues are necessary and sufficient to bind to Src.
Survivin1–10 is a MTS
By fusing the first 30 nucleotides of the human survivin gene to
GFP cDNAwe engineeredMGAPTLPPAW–GFP.When expressed
in HeLa cells we discovered that it localised to mitochondria
(Fig. 2A). To verify this biochemically, cells expressing GFP or
survivin1–10–GFP were fractionated by differential centrifugation,
and whole-cell extracts and mitochondrial-enriched fractions were
probed with anti-GFP antibodies (Fig. 2B). Anti-VDAC and anti-
tubulin antibodies were used to identify mitochondrial fractions and
cytoplasmic contamination, respectively. Survivin1–10–GFP was
clearly present in the mitochondrial fraction, whereas GFP was
excluded (Fig. 2B). Next, super-resolution microscopy was used to
image survivin1–10–GFP in living cells. Structured illumination
showed that survivin1–10–GFP was coincident with MitoTracker
throughout the mitochondria rather than simply binding to the
exterior (Fig. 2C). To ascertain whether survivin1–10–GFP could be
targeted to the mitochondria independently of any cofactors,
we in vitro translated (IVT) [35S]methionine-labelled GFP or
survivin1–10–GFP to compare their import into isolated
mitochondria, using the MTS of cytochromec oxidase subunit
VIIIA as a positive control (MTS–GFP). Fig. 2D shows the IVT
protein and radiolabelling, followed by assessment of association of
each protein with the mitochondria after washing in buffer (control),
after incubation in trypsin (to remove exteriorly bound proteins), or
after trypsin and Triton X-100, which eliminates all proteins, GFP
acted as negative control; its signal was low after the control wash,
and eliminated by trypsin treatment, highlighting its failure to be
imported. In contrast, MTS–GFP, survivin1–10–GFP and survivin–
GFP were successfully imported into the mitochondria, as
evidenced by protein remaining after trypsin treatment. These data
suggest that survivin1–10–GFP and survivin–GFP are mitochondrial
residents and can enter this organelle independently of cofactors.
MTSs are normally N-terminally placed amphiphilic stretches of
17–40 amino acids that tend to form amphipathic α-helices that
engage with translocase complexes of the outer and inner
mitochondrial membrane. The mitochondrial localisation of
survivin1–10 and its ability to access isolated mitochondria in vitro
suggest that it is a bona fide MTS despite its short length. Consistent
with this, survivin1–10 conforms to the amphiphilic requirements of
a canonical MTSwhen mapped on a hydropathy plot (Fig. 2E), with
hydrophobic residues predominantly on one side, and hydrophilic
residues on the other.
The N-terminus of survivin regulates substrate adhesion
While handling, we noted that cells expressing survivin1–10–GFP
grew more rapidly than controls (Fig. 2F) and were less adherent
(Fig. 3A). To determine whether the proline residues were
required for adhesion, we replaced them with alanine residues
(survivin1–10ΔP–GFP) and transiently expressed this mutated protein
into HeLa cells. Proline-to-alanine replacement restored focal
adhesions and F-actin assembly (Fig. 3A). Moreover, when
observed live, the percentage of unspread or floating cells was
reduced from 96.2% (n=104) cells expressing survivin1–10–GFP, to
10.8% (n=277) in cells expressing survivin1–10ΔP–GFP. Live imaging
also revealed that mitochondrial targeting was abolished by proline-
to-alanine mutation (Fig. 3B). The presence of both a proline-rich
sequence and aMTS in theN-terminus fits with a precedent described
for Dok4 (Itoh et al., 2005) and HTLV1 (Tibaldi et al., 2011),
suggesting that it is a Src-regulator and a mitochondrial chaperone.
Conclusion
We report the novel findings that the N-terminus of survivin is both
a Src regulator and an MTS. The data suggest that much of what
survivin achieves in cancer might be accomplished in collaboration
with Src.
MATERIALS AND METHODS
Unless otherwise indicated, tissue culture reagents were obtained from
Invitrogen, cloning enzymes from NEB, and all other reagents from Sigma-
Aldrich.
Molecular cloning
Wild-type survivin1–10–GFP was generated by annealing two primers
corresponding to the first 30 nucleotides of human survivin cDNA, with 5′
EcoRI and 3′ HindIII sites. The annealed DNA fragment was ligated into
pBS-GFP then shuttled into pcDNA3.1 (Invitrogen) using EcoRI and Xho1.
The triple mutation that translates to MGAaTLaaAW (lowercase letters
indicate the mutated residues) wasmade by site-directed mutagenesis with the
5′ primer 5′-ATGGGTGCCGCGACGTTGGCCGCTGCCTGG-3′ and 3′
primer 5′-CCAGGCAGCGGCCAACGTCGCGGCACCCAT-3′ (Eurofins,
MWG Operon), Vent polymerase, dNTPs and survivin1–10–GFP cDNA as
template, using Stratagene Quickchange II kit (Agilent Technologies). The
template was digested with DpnI and nascent cDNA transformed into
competent DH5α E.coli cells. All sequences were verified prior to use.
Cell culture and proliferation
HeLa cells (derived from ATCC stock) were cultured at 37°C in 5% CO2
humidified incubator inDulbecco’sModified Eagle’sMedium (DMEM)with
10%HyClone fetal bovine serum (FBS), L-glutamine (2 mM), 1% penicillin-
streptomycin and 1% fungizone. To create lines stably expressingGFP-tagged
proteins, cells in antibiotic-free DMEM were transfected with pcDNA3.1
constructs using FuGENE 6 (Promega) in Opti-MEM. To select for positive
transformants, G418 (50 μg/ml) was added 24 h post transfection and sorted
by FACS. Cell number was assessed using a resazurin-based assay in which
cells were incubated for 1 h at 37°C in 10 μg/ml resazurin in DMEM and
measured spectrophotometrically (FLUOstar Galaxy, BMGLabtechnologies)
with excitation at 530 nm and emission at 590 nm.
Mitochondrial assays
Fractionation
106 cells were resuspended in mitochondrial isolation buffer (10 mM
HEPES, pH 7.5, 200 mM mannitol, 1 mM EGTA and 70 nM sucrose with
protease inhibitors), and lysed with 25 strokes in a 2-cm3 glass homogeniser.
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Nuclei were removed by a 5-min centrifugation at 1000 g. The supernatant
was re-spun (2000 g) to remove contaminating nuclei, then spun at 10,000 g,
(15 min, 4°C) to pellet mitochondria, which were re-washed and pelleted
two more times to ensure purity.
Import
GFP, MTS–GFP, survivin1–10–GFP and survivin–GFP were translated
in vitro (IVT) from pcDNA templates using T7 RNA polymerase,
incorporating [35S]methionine using a rabbit reticulocyte lysate system
(Promega). Radiolabelled proteins were incubated for 1 h at 37°C with
mitochondria isolated from HeLa cells in import buffer [20 mM HEPES
pH7.5, 3% (w/v) fatty acid-free BSA, 250 mM sucrose, 80 mM KCl, 5 mM
MgCl2 supplemented with 2 mM ATP and 10 mM sodium succinate],
before washing in buffer or incubation in 150 µg/ml trypsin or trypsin plus
1% Triton X-100 (15 min, on ice).
Immunoblotting
Cell lysates were prepared in M-PER (ThermoFisher, 45 min, room
temperature), with standard protease (1 µg/ml) and phosphatase inhibitors
including 2 mM sodium orthovanadate. Standard procedures were used
for SDS-PAGE (12%) and transfer to nitrocellulose (PALL). To detect
GFP-tagged proteins, membranes were probed with anti-GFP antibodies
(catalogue no. 11814460001, 1:1000, Roche). Additional primary antibodies
used were against: tubulin (B512, 1:2000, Sigma); Src (SC-18, 1:1000, Santa
Fig. 2. The first ten amino acids of survivin are an MTS. (A) HeLa cells expressing survivin1–10–GFP (1-10-GFP) or GFP (green) were grown on poly-L-lysine-
coated slides, stained with MitoTracker (red) and imaged live. Scale bars: 20 µm (upper) and 5 µm (lower). (B) Immunoblot of fractionated cells: 25 µg each of
whole-cell extracts (WCE) and the cytoplasmic fraction (cyto), and 8 µg of themitochondrial fraction (mito). Anti-GFPantibody detects GFPand survivin1–10–GFP,
and anti-VDAC and anti-tubulin antibodies highlight mitochondrial and cytoplasmic fractions, respectively. (C) Structured illumination of mitochondria in live
cells expressing survivin1–10–GFP stained with MitoTracker. Scale bar: 1 µm. (D) Mitochondrial import assay: GFP, MTS–GFP, survivin1–10–GFP and
survivin–GFP translated in vitro (IVT), labelled with [35S]methionine then incubated with mitochondria isolated from HeLa cells for 1 h at 37°C. Mitochondria were
washed in isolation buffer (control) or treated with 150 µg/ml trypsin (trp) or trypsin and 1% Triton X-100 (tri). Mitochondrial retention of proteins was assessed by
SDS-PAGE and phosphor-imaging. (E) Hydropathy wheel plot of the first ten residues of survivin. Residue type: circles, hydrophilic; diamonds, hydrophobic.
Hydrophobicity scale is green (high) to yellow (zero). Hydrophilicity scale is red (high) to orange (low). (F) The rate of cell growth of each line was compared in
exponential phase. Mean±s.d. of three independent experiments is shown. A paired t-test demonstrated that the increased growth rate of 1-10-GFP cells is
significantly different from the GFP control, variance in other lines was not significant (ns). 11-42-GFP, survivin11–142–GFP; SVN-GFP, survivin–GFP.
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Cruz Biotechnology); phospho-SrcY416 (catalogue no. 6943, 1:1000, Cell
Signalling); VDAC (D73D12, 1:1000, Cell Signalling). Incubations were
carried out in PBS with 5% milk and 0.1% Tween 20, except for phospho-
SrcY416, for which TBST and 5% BSA was used. Horseradish peroxidise
(HRP)-conjugated secondary antibodies (DAKO, 1:2000), enhanced
chemiluminescence (GeneFlow) and X-ray film (GE Healthcare) were used
to detect bands.
Immunoprecipitation
Cells (3×106) were harvested by scraping and lysed in 200 µl lysis buffer
(10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40)
supplemented with standard protease inhibitors, 2 U benzonase and 2 mM
MgCl2. Lysates were clarified by centrifugation (20,000 g, 2 min, 4°C) then
diluted in dilution buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM
EDTA). For every 500 µl of extract, 25 µl of prewashed GFP-trap_A beads
(50% slurry, Chromotek) were added (note that the exact quantity was
optimised to the expression of GFP-tagged protein in each sample). Lysates
and beads were incubated for 1 h at 4°C with rotation, then pelleted by
centrifugation at 2500 g for 2 min at 4°C and washed in ice-cold dilution
buffer. Proteins were boiled off the beads (95°C for 10 min) in lysis buffer
with SDS-sample buffer.
Microscopy
Fixed-cell imaging
Cells were cultured on glass coverslips with or without poly-L-lysine, then
fixed with 4% formaldehyde, permeabilised using 0.15% Triton X-100 in
PBS, and blocked with 1% BSA before immunoprobing with anti-vinculin
antibodies (catalogue no. 73614, 1:1000, Santa Cruz Biotechnology, 1 h
room temperature), and Cy5-secondary anti-rabbit-IgG antibodies (1:1000,
AbCam; 1 h room temperature). Samples were counterstained with 20 nM
Fig. 3. Survivin1-10–GFP is a proline-rich sequence that
reduces cell adhesion. (A) Cells expressing survivin1-10 –
GFP or survivin1-10ΔP-GFP (green, 1-10-GFP and 1-10ΔP-
GFP, respectively) were grown on uncoated glass coverslips,
stained as in Fig. 1A and viewed with objectives of the
indicated magnification. (B) Live cells expressing
survivin1-10ΔP–GFP stained with MitoTracker viewed with
objectives of the indicated magnification. Scale bars: 10 µm.
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Rhodamine–phalloidin and DAPI, then mounted withMowiol. Images were
acquired using an inverted (Olympus IX71) microscope with 40× NA1.2 oil
and 60× NA1.4 oil objectives, DeltaVision software (GE Healthcare) and a
Coolsnap HQ2 camera (Photometrics). Maximum projections of
deconvolved 0.3-μm z-stacks prepared in Photoshop are presented.
Live-cell imaging
Cells were grown in glass-bottomed dishes (Willco) with or without poly-L-
lysine. Prior to imaging, medium was replaced with MitoTracker® CMXRos
(25 nM) in Phenol-Red-free CO2-independent medium and imaged as above.
For super-resolution microscopy, a Zeiss Elyra PS.1 microscope was used in
structured illumination mode, with the following settings: objective Plan-
Apochromat 63×1.4 oil DIC M27, filter set LBF-488/561 and cmos camera
exposure time 20 ms. Two imaging tracks were set up in fast frame mode,
which alternates the excitation lasers (solid state 488 nm and 561 nm at 20%
and10% laser power settings, respectively).Channel alignmentwas confirmed
using 100-nm beads scanned with the same settings. Image processing and
alignment was carried out using Zeiss Zen Black 2012 software.
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